Doctors are hailing a new way to treat serious asthma and chronic obstructive pulmonary disease attacks that marks the first breakthrough for 50 years and could be a “gamechanger” for patients.
A trial found offering patients an injection was more effective than the current care of steroid tablets, and cuts the need for further treatment by 30%.
The results, published in the Lancet Respiratory Medicine journal, could be transformative for millions of people with asthma and COPD around the world.
Benralizumab is a monoclonal antibody that targets specific white blood cells, called eosinophils, to reduce lung inflammation. It is used as a repeat treatment for severe asthma at a low dose, but the trial found a higher single dose could be very effective if injected at the time of a flare-up.
Lead investigator Prof Mona Bafadhel, of King’s College London, said: “This could be a gamechanger for people with asthma and COPD. Treatment for asthma and COPD exacerbations have not changed in 50 years, despite causing 3.8m deaths worldwide a year combined.
“Benralizumab is a safe and effective drug already used to manage severe asthma. We’ve used the drug in a different way – at the point of an exacerbation – to show that it’s more effective than steroid tablets, which is the only treatment currently available.”